SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.

BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $116.85 and last traded at $112.44, with a volume of 2702748 shares. The stock had previously closed at $115.13. Wall Street Analyst Weigh In A number of brokerages have weighed in on HALO.

Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Ratings This is a breakdown of recent ratings

The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. FTNT, ABBNY, EAT and HALO are some such stocks.

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PR NewswireSAN DIEGO, Sept. 17, 20

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes").

Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,740,561 shares of the biopharmaceutical company's stock, valued at approximately $214,504,000. Bank of America Corp DE owned

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes").